Covered recipient · General Payments record
NIHAL E ABDULLA
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$2,704.13
119 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,321.20 | 114 |
| Honoraria | $350.00 | 2 |
| Education | $32.93 | 3 |
By paying entity
PY2020 · entire year · sorted by reported total
Page 2 of 3; records 51–100 of 119 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
NIHAL E ABDULLA
NPI 1750585345 · CMS profile ID 79323
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
LOS ALAMITOS, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 119 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1750585345?year=2020&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- NIHAL E ABDULLA, NPI 1750585345, CMS profile ID 79323. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 119 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750585345?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). NIHAL E ABDULLA, NPI 1750585345, CMS profile ID 79323. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 119 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750585345?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- NIHAL E ABDULLA, NPI 1750585345, CMS profile ID 79323, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 119 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1750585345?year=2020&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
119 matching records · $2,704.13 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 119.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Heron Therapeutics, Inc. | $20.91 | 07/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 717818829 | CMS |
| Seagen Inc. | $24.73 | 07/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 732439769 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.30 | 07/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727798223 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2.25 | 07/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727798225 | CMS |
| Incyte Corporation | $13.36 | 07/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 745810033 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $24.97 | 07/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747325989 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.95 | 06/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736168473 | CMS |
| E.R. Squibb & Sons, L.L.C. | $18.40 | 06/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727798213 | CMS |
| Janssen Biotech, Inc. | $35.65 | 06/24/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719334609 | CMS |
| E.R. Squibb & Sons, L.L.C. | $8.18 | 06/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727798217 | CMS |
| GENZYME CORPORATION | $21.84 | 06/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744204819 | CMS |
| Incyte Corporation | $24.70 | 06/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 745810019 | CMS |
| Amgen Inc. | $17.19 | 06/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741250007 | CMS |
| Agios Pharmaceuticals, Inc. | $15.15 | 06/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751970627 | CMS |
| Amgen Inc. | $10.41 | 06/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741250017 | CMS |
| Janssen Biotech, Inc. | $16.42 | 06/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719334603 | CMS |
| Alexion Pharmaceuticals, Inc. | $17.90 | 05/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 726635531 | CMS |
| E.R. Squibb & Sons, L.L.C. | $24.08 | 05/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727798207 | CMS |
| Seagen Inc. | $20.02 | 05/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 732439737 | CMS |
| PFIZER INC. | $15.59 | 05/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743202723 | CMS |
| GENZYME CORPORATION | $19.85 | 05/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744204825 | CMS |
| AbbVie Inc. | $22.91 | 05/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721659665 | CMS |
| Janssen Biotech, Inc. | $18.32 | 05/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719334597 | CMS |
| Janssen Pharmaceuticals, Inc | $14.67 | 05/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719334589 | CMS |
| Incyte Corporation | $23.32 | 05/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 745810009 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $24.46 | 05/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725665657 | CMS |
| Amgen Inc. | $17.04 | 04/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741249989 | CMS |
| Genentech USA, Inc. | $18.19 | 04/24/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743074163 | CMS |
| Janssen Biotech, Inc. | $22.21 | 04/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719334605 | CMS |
| GENZYME CORPORATION | $22.74 | 04/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744204791 | CMS |
| Amgen Inc. | $23.39 | 04/17/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741250015 | CMS |
| E.R. Squibb & Sons, L.L.C. | $26.14 | 04/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727798197 | CMS |
| Amgen Inc. | $23.41 | 04/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741250001 | CMS |
| Amgen Inc. | $24.09 | 04/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741250005 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.98 | 04/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727798201 | CMS |
| Amgen Inc. | $25.31 | 03/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741249993 | CMS |
| E.R. Squibb & Sons, L.L.C. | $18.74 | 03/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727798195 | CMS |
| E.R. Squibb & Sons, L.L.C. | $6.25 | 03/13/2020 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727798183 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.27 | 03/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 727798191 | CMS |
| Merck Sharp & Dohme Corporation | $19.21 | 03/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747729423 | CMS |
| PFIZER INC. | $10.30 | 03/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743804157 | CMS |
| Daiichi Sankyo Inc. | $19.94 | 03/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739489415 | CMS |
| Ipsen Biopharmaceuticals, Inc | $30.84 | 03/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741937249 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $26.53 | 03/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720871401 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $26.89 | 03/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815204879 | CMS |
| Daiichi Sankyo Inc. | $20.46 | 02/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739513035 | CMS |
| Amgen Inc. | $29.80 | 02/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741249999 | CMS |
| Lilly USA, LLC | $1.53 | 02/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728576961 | CMS |
| Lilly USA, LLC | $3.83 | 02/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728580089 | CMS |
| Lilly USA, LLC | $19.17 | 02/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728586995 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,514,624.98 | 147 |
| PY2024 | Principal investigator | $1,076,950.03 | 67 |
| PY2023 | Principal investigator | $497,917.11 | 20 |
| PY2022 | Principal investigator | $375,809.84 | 7 |
| PY2021 | Recipient | $480.95 | 1 |
| PY2021 | Principal investigator | $100,502.71 | 5 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
147 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $134,320.64 | 12/31/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic | An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Participants with HR,HER2-Unresectable Locally Advanced or Metastatic Breast Cancer | No dispute reported | 06/30/2026 | 1232923502 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $5,665.24 | 12/31/2025 | Non-covered Recipient Entity Cancer Blood and Specialty Clinic | A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metast | No dispute reported | 06/30/2026 | 1232927787 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $27,784.63 | 12/31/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic | A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK 3475A Versus Intravenous Pembrolizumab, in the First-line Treatment of Participants With Metasta | No dispute reported | 06/30/2026 | 1232928894 |
| Principal investigator 1 | PFIZER INC. | $5,796.24 | 12/31/2025 | Non-covered Recipient Entity Cancer and Blood Research Center LLC | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228750990 |
| Principal investigator 1 | PFIZER INC. | $1,958.18 | 12/27/2025 | Non-covered Recipient Entity Cancer and Blood Research Center LLC | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228725392 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,861.00 | 12/22/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175436582 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,324.00 | 12/19/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib | No dispute reported | 06/30/2026 | 1175436575 |
| Principal investigator 1 | PFIZER INC. | $343,803.60 | 12/19/2025 | Non-covered Recipient Entity Cancer and Blood Research Center | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228715879 |
| Principal investigator 1 | PFIZER INC. | $22.50 | 12/19/2025 | Non-covered Recipient Entity Cancer and Blood Research Center | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228716057 |
| Principal investigator 1 | PFIZER INC. | $37.50 | 12/17/2025 | Non-covered Recipient Entity Cancer and Blood Research Center | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228716063 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $2,000.00 | 12/15/2025 | Non-covered Recipient Entity Cancer Blood and Specialty Clinic | A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metast | No dispute reported | 06/30/2026 | 1232927743 |
| Principal investigator 1 | PFIZER INC. | $18,693.22 | 12/13/2025 | Non-covered Recipient Entity Cancer and Blood Research Center LLC | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228745054 |
| Principal investigator 1 | BeOne Medicines Ltd. | $31,440.00 | 12/10/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190337097 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,439.81 | 12/10/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190337103 |
| Principal investigator 1 | BeOne Medicines Ltd. | $6,990.00 | 12/09/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190328243 |
| Principal investigator 1 | PFIZER INC. | $15.00 | 12/09/2025 | Non-covered Recipient Entity Cancer and Blood Research Center | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228716155 |
| Principal investigator 1 | PFIZER INC. | $3,916.36 | 11/26/2025 | Non-covered Recipient Entity Cancer and Blood Research Center LLC | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228723734 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,500.00 | 11/24/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL | A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Cetrelimab Combination Therapy in Metastatic Non-small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175436749 |
| Principal investigator 1 | Genentech, Inc. | $7,329.00 | 11/20/2025 | Non-covered Recipient Entity CANCER + BLOOD RESEARCH CENTER LLC | Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC | No dispute reported | 06/30/2026 | 1211582862 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,439.81 | 11/18/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190330165 |
| Principal investigator 1 | PFIZER INC. | $22.50 | 11/18/2025 | Non-covered Recipient Entity Cancer and Blood Research Center | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228716059 |
| Principal investigator 1 | PFIZER INC. | $1,690.88 | 11/05/2025 | Non-covered Recipient Entity Cancer and Blood Research Center LLC | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228737322 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,259.00 | 11/03/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib | No dispute reported | 06/30/2026 | 1175436786 |
| Principal investigator 1 | PFIZER INC. | $53,894.01 | 10/31/2025 | Non-covered Recipient Entity Cancer and Blood Research Center LLC | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228741066 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,439.81 | 10/21/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336789 |
| Principal investigator 1 | PFIZER INC. | $7,640.05 | 10/15/2025 | Non-covered Recipient Entity Cancer and Blood Research Center | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228715713 |
| Principal investigator 1 | PFIZER INC. | $91,680.90 | 10/15/2025 | Non-covered Recipient Entity Cancer and Blood Research Center | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228716151 |
| Principal investigator 1 | PFIZER INC. | $45,840.45 | 10/14/2025 | Non-covered Recipient Entity Cancer and Blood Research Center | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228716153 |
| Principal investigator 1 | PFIZER INC. | $7.50 | 10/14/2025 | Non-covered Recipient Entity Cancer and Blood Research Center | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228716339 |
| Principal investigator 1 | Janssen Research & Development, LLC | $490.00 | 10/13/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib | No dispute reported | 06/30/2026 | 1175436698 |
| Principal investigator 1 | PFIZER INC. | $37.50 | 10/13/2025 | Non-covered Recipient Entity Cancer and Blood Research Center | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228715881 |
| Principal investigator 1 | PFIZER INC. | $114,601.20 | 10/13/2025 | Non-covered Recipient Entity Cancer and Blood Research Center | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228715977 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $31,666.18 | 10/10/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | An open-label, randomized, multicenter, Phase 3 study to assess the efficacy and safety of Trastuzumab Deruxtecan as first-line treatment of unresectable, locally advanced or metastatic NSCLC harboring a HER2 exon 19 or 20 mutation (DESTINY-Lung04) | No dispute reported | 06/30/2026 | 1185549485 |
| Principal investigator 1 | PFIZER INC. | $11,095.68 | 10/09/2025 | Non-covered Recipient Entity Cancer and Blood Research Center LLC | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228756855 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,961.00 | 10/06/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib | No dispute reported | 06/30/2026 | 1175436839 |
| Principal investigator 1 | BeOne Medicines Ltd. | $6,212.00 | 09/30/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190328239 |
| Principal investigator 1 | PFIZER INC. | $21,894.34 | 09/24/2025 | Non-covered Recipient Entity Cancer and Blood Research Center LLC | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228750032 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,439.81 | 09/23/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336881 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,387.00 | 09/22/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175436449 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,392.00 | 09/22/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175436681 |
| Principal investigator 1 | Genentech, Inc. | $7,929.00 | 09/17/2025 | Non-covered Recipient Entity CANCER + BLOOD RESEARCH CENTER LLC | Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC | No dispute reported | 06/30/2026 | 1211582857 |
| Principal investigator 1 | BeOne Medicines Ltd. | $47,160.00 | 09/16/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336911 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,898.00 | 09/04/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175436378 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $66,582.76 | 08/31/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic | A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative Breast Cancer TNBC Who Received | No dispute reported | 06/30/2026 | 1232924344 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $43,191.60 | 08/31/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic | A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK 3475A Versus Intravenous Pembrolizumab, in the First-line Treatment of Participants With Metasta | No dispute reported | 06/30/2026 | 1232928896 |
| Principal investigator 1 | PFIZER INC. | $4,390.88 | 08/29/2025 | Non-covered Recipient Entity Cancer and Blood Research Center LLC | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228765955 |
| Principal investigator 1 | PFIZER INC. | $114,601.20 | 08/26/2025 | Non-covered Recipient Entity Cancer and Blood Research Center | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228715709 |
| Principal investigator 1 | PFIZER INC. | $60.00 | 08/26/2025 | Non-covered Recipient Entity Cancer and Blood Research Center | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228715883 |
| Principal investigator 1 | BeOne Medicines Ltd. | $15,720.00 | 08/20/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190342207 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,439.81 | 08/20/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190342212 |
| Principal investigator 1 | BeOne Medicines Ltd. | $7,801.00 | 08/19/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190328237 |
| Principal investigator 1 | PFIZER INC. | $57,300.60 | 08/15/2025 | Non-covered Recipient Entity Cancer and Blood Research Center | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228715885 |
| Principal investigator 1 | PFIZER INC. | $5,063.18 | 07/31/2025 | Non-covered Recipient Entity Cancer and Blood Research Center LLC | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228772521 |
| Principal investigator 1 | BeOne Medicines Ltd. | $17,654.00 | 07/22/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190328241 |
| Principal investigator 1 | PFIZER INC. | $114,601.20 | 07/22/2025 | Non-covered Recipient Entity Cancer and Blood Research Center | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228715979 |
| Principal investigator 1 | PFIZER INC. | $45,840.45 | 07/22/2025 | Non-covered Recipient Entity Cancer and Blood Research Center | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228715983 |
| Principal investigator 1 | PFIZER INC. | $22.50 | 07/22/2025 | Non-covered Recipient Entity Cancer and Blood Research Center | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228716061 |
| Principal investigator 1 | PFIZER INC. | $15.00 | 07/10/2025 | Non-covered Recipient Entity Cancer and Blood Research Center | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228715981 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $17,500.00 | 07/07/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic | A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK 3475A Versus Intravenous Pembrolizumab, in the First-line Treatment of Participants With Metasta | No dispute reported | 06/30/2026 | 1232928692 |
| Principal investigator 1 | Janssen Research & Development, LLC | $240.00 | 06/30/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175436500 |
| Principal investigator 1 | Janssen Research & Development, LLC | $21,353.00 | 06/30/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | Investigation-specific Appendix 3 to Master Protocol PLATFORMPANSC2001 (KALEIDOSCOPE) A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175436609 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,975.00 | 06/30/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175436730 |
| Principal investigator 1 | BeOne Medicines Ltd. | $25,838.16 | 06/26/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190342278 |
| Principal investigator 1 | PFIZER INC. | $22,536.00 | 06/26/2025 | Non-covered Recipient Entity Cancer and Blood Research Center LLC | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228792298 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,571.00 | 06/23/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175436644 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,439.81 | 06/12/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190337006 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,879.04 | 06/12/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190337012 |
| Principal investigator 1 | Janssen Research & Development, LLC | $240.00 | 06/12/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175436546 |
| Principal investigator 1 | Janssen Research & Development, LLC | $362.00 | 06/12/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175436558 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,879.04 | 06/11/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190337042 |
| Principal investigator 1 | Genentech, Inc. | $7,756.00 | 06/11/2025 | Non-covered Recipient Entity CANCER + BLOOD RESEARCH CENTER LLC | Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC | No dispute reported | 06/30/2026 | 1211582846 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,516.00 | 06/09/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | Investigation-specific Appendix 3 to Master Protocol PLATFORMPANSC2001 (KALEIDOSCOPE) A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175436367 |
| Principal investigator 1 | Genentech, Inc. | $24,469.60 | 06/03/2025 | Non-covered Recipient Entity CANCER + BLOOD RESEARCH CENTER LLC | PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC | No dispute reported | 06/30/2026 | 1211582866 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,394.00 | 05/29/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175436455 |
| Principal investigator 1 | PFIZER INC. | $57,300.60 | 05/27/2025 | Non-covered Recipient Entity Cancer and Blood Research Center | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228723878 |
| Principal investigator 1 | PFIZER INC. | $15.00 | 05/27/2025 | Non-covered Recipient Entity Cancer and Blood Research Center | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228761186 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,753.00 | 05/26/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | Investigation-specific Appendix 3 to Master Protocol PLATFORMPANSC2001 (KALEIDOSCOPE) A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175436554 |
| Principal investigator 1 | BeiGene, Ltd. | $20,633.00 | 05/20/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325116 |
| Principal investigator 1 | BeiGene, Ltd. | $1,439.81 | 05/15/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190323544 |
| Principal investigator 1 | BeiGene, Ltd. | $4,697.60 | 05/15/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190323546 |
| Principal investigator 1 | BeiGene, Ltd. | $15,720.00 | 05/12/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190323556 |
| Principal investigator 1 | ABBVIE INC. | $5,498.55 | 05/07/2025 | Non-covered Recipient Entity CANCER BLOOD AND SPECIALTY CLINIC | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202482445 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,536.00 | 05/05/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175436563 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,256.00 | 05/05/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175436597 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,616.00 | 05/05/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175436726 |
| Principal investigator 1 | BeiGene, Ltd. | $2,625.00 | 04/29/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190323064 |
| Principal investigator 1 | Genentech, Inc. | $5,354.00 | 04/29/2025 | Non-covered Recipient Entity CANCER + BLOOD RESEARCH CENTER LLC | PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC | No dispute reported | 06/30/2026 | 1211582895 |
| Principal investigator 1 | BeiGene, Ltd. | $1,439.81 | 04/17/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190323588 |
| Principal investigator 1 | BeiGene, Ltd. | $1,879.04 | 04/17/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190323590 |
| Principal investigator 1 | BeiGene, Ltd. | $9,395.20 | 04/17/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190323592 |
| Principal investigator 1 | Genentech, Inc. | $482.00 | 04/15/2025 | Non-covered Recipient Entity CANCER + BLOOD RESEARCH CENTER LLC | PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC | No dispute reported | 06/30/2026 | 1211582886 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $25,490.70 | 04/09/2025 | Non-covered Recipient Entity HIGHLAND MEDICAL HEMATOLOGY AND ONCOLOGY | An open-label, randomized, multicenter, Phase 3 study to assess the efficacy and safety of Trastuzumab Deruxtecan as first-line treatment of unresectable, locally advanced or metastatic NSCLC harboring a HER2 exon 19 or 20 mutation (DESTINY-Lung04) | No dispute reported | 06/30/2026 | 1185549483 |
| Principal investigator 1 | BeiGene, Ltd. | $9,985.00 | 04/08/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325118 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $3,481.40 | 04/04/2025 | Non-covered Recipient Entity Cancer And Blood Specialty Clinic | A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation | No dispute reported | 06/30/2026 | 1236531223 |
| Principal investigator 1 | BeiGene, Ltd. | $9,395.20 | 04/03/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321890 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,275.00 | 03/31/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175436417 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,390.00 | 03/31/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175436569 |
| Principal investigator 1 | Genentech, Inc. | $1,684.00 | 03/26/2025 | Non-covered Recipient Entity CANCER + BLOOD RESEARCH CENTER LLC | PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC | No dispute reported | 06/30/2026 | 1211582890 |
| Principal investigator 1 | BeiGene, Ltd. | $4,697.60 | 03/24/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321900 |
| Principal investigator 1 | BeiGene, Ltd. | $15,720.00 | 03/24/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321902 |
| Principal investigator 1 | BeiGene, Ltd. | $1,439.81 | 03/24/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321904 |
| Principal investigator 1 | BeiGene, Ltd. | $8,612.72 | 03/24/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321906 |
| Principal investigator 1 | BeiGene, Ltd. | $1,879.04 | 03/24/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321908 |
| Principal investigator 1 | Genmab U.S., Inc. | $3,450.00 | 03/20/2025 | Non-covered Recipient Entity CANCER AND BLOOD SPECIALTY CLINIC | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235929981 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,000.00 | 03/20/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | Investigation-specific Appendix 3 to Master Protocol PLATFORMPANSC2001 (KALEIDOSCOPE) A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175436477 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $10,920.00 | 03/19/2025 | Non-covered Recipient Entity Cancer And Blood Specialty Clinic | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | No dispute reported | 06/30/2026 | 1236531218 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,066.00 | 03/10/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175436372 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,335.00 | 03/10/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175436792 |
| Principal investigator 1 | BeiGene, Ltd. | $15,720.00 | 03/03/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325264 |
| Principal investigator 1 | BeiGene, Ltd. | $4,319.43 | 03/03/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325266 |
| Principal investigator 1 | BeiGene, Ltd. | $8,612.72 | 03/03/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325268 |
| Principal investigator 1 | BeiGene, Ltd. | $939.52 | 03/03/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325278 |
| Principal investigator 1 | BeiGene, Ltd. | $939.52 | 03/03/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325280 |
| Principal investigator 1 | BeiGene, Ltd. | $4,697.60 | 03/03/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325282 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,309.00 | 03/03/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175436593 |
| Principal investigator 1 | BeiGene, Ltd. | $31,440.00 | 02/27/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325286 |
| Principal investigator 1 | BeiGene, Ltd. | $4,319.43 | 02/27/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325288 |
| Principal investigator 1 | BeiGene, Ltd. | $25,838.16 | 02/27/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325290 |
| Principal investigator 1 | BeiGene, Ltd. | $7,516.16 | 02/27/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325292 |
| Principal investigator 1 | BeiGene, Ltd. | $14,092.80 | 02/27/2025 | Non-covered Recipient Entity Cancer and Blood Specialty Clinic - Los Alamitos | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325294 |
| Principal investigator 1 | Genmab U.S., Inc. | $1,100.00 | 02/20/2025 | Non-covered Recipient Entity CANCER AND BLOOD SPECIALTY CLINIC | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235929953 |
| Principal investigator 1 | Genmab U.S., Inc. | $4,667.00 | 02/20/2025 | Non-covered Recipient Entity CANCER AND BLOOD SPECIALTY CLINIC | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235929956 |
| Principal investigator 1 | Genmab U.S., Inc. | $2,000.00 | 02/20/2025 | Non-covered Recipient Entity CANCER AND BLOOD SPECIALTY CLINIC | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235929964 |
| Principal investigator 1 | Genmab U.S., Inc. | $4,716.40 | 02/20/2025 | Non-covered Recipient Entity CANCER AND BLOOD SPECIALTY CLINIC | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235929971 |
| Principal investigator 1 | Genmab U.S., Inc. | $1,041.70 | 02/20/2025 | Non-covered Recipient Entity CANCER AND BLOOD SPECIALTY CLINIC | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235929974 |
| Principal investigator 1 | Genmab U.S., Inc. | $2,850.00 | 02/20/2025 | Non-covered Recipient Entity CANCER AND BLOOD SPECIALTY CLINIC | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235929985 |
| Principal investigator 1 | Janssen Research & Development, LLC | $310.00 | 02/19/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175436533 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,392.00 | 02/19/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175436816 |
| Principal investigator 1 | AstraZeneca UK Limited | $38,585.70 | 02/14/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 | No dispute reported | 06/30/2026 | 1185549481 |
| Principal investigator 1 | Genentech, Inc. | $480.30 | 02/14/2025 | Non-covered Recipient Entity CANCER + BLOOD RESEARCH CENTER LLC | PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC | No dispute reported | 06/30/2026 | 1211582870 |
| Principal investigator 1 | Genentech, Inc. | $8,955.00 | 02/14/2025 | Non-covered Recipient Entity CANCER + BLOOD RESEARCH CENTER LLC | PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC | No dispute reported | 06/30/2026 | 1211582882 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $14,665.10 | 02/12/2025 | Non-covered Recipient Entity CANCER AND BLOOD SPECIALTY CLINIC | An open-label, randomized, multicenter, Phase 3 study to assess the efficacy and safety of Trastuzumab Deruxtecan as first-line treatment of unresectable, locally advanced or metastatic NSCLC harboring a HER2 exon 19 or 20 mutation (DESTINY-Lung04) | No dispute reported | 06/30/2026 | 1185549479 |
| Principal investigator 1 | Janssen Research & Development, LLC | $26,442.00 | 02/03/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175436520 |
| Principal investigator 1 | Janssen Research & Development, LLC | $50,500.00 | 01/31/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175436736 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,323.89 | 01/29/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LLC | A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) | No dispute reported | 06/30/2026 | 1185549487 |
| Principal investigator 1 | Genentech, Inc. | $9,022.00 | 01/28/2025 | Non-covered Recipient Entity CANCER + BLOOD RESEARCH CENTER LLC | Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC | No dispute reported | 06/30/2026 | 1211582849 |
| Principal investigator 1 | Genentech, Inc. | $66,490.00 | 01/23/2025 | Non-covered Recipient Entity CANCER + BLOOD RESEARCH CENTER LLC | PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC | No dispute reported | 06/30/2026 | 1211582874 |
| Principal investigator 1 | Genentech, Inc. | $3,588.00 | 01/23/2025 | Non-covered Recipient Entity CANCER + BLOOD RESEARCH CENTER LLC | PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC | No dispute reported | 06/30/2026 | 1211582878 |
| Principal investigator 1 | Genentech, Inc. | $18,157.00 | 01/22/2025 | Non-covered Recipient Entity CANCER + BLOOD RESEARCH CENTER LLC | Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC | No dispute reported | 06/30/2026 | 1211582854 |
| Principal investigator 1 | Genmab U.S., Inc. | $700.00 | 01/16/2025 | Non-covered Recipient Entity CANCER AND BLOOD SPECIALTY CLINIC | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235929949 |
| Principal investigator 1 | Genmab U.S., Inc. | $19,613.10 | 01/16/2025 | Non-covered Recipient Entity CANCER AND BLOOD SPECIALTY CLINIC | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235929960 |
| Principal investigator 1 | Genmab U.S., Inc. | $7,998.90 | 01/16/2025 | Non-covered Recipient Entity CANCER AND BLOOD SPECIALTY CLINIC | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235929968 |
| Principal investigator 1 | Genmab U.S., Inc. | $1,050.00 | 01/16/2025 | Non-covered Recipient Entity CANCER AND BLOOD SPECIALTY CLINIC | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235929978 |
| Principal investigator 1 | Genmab U.S., Inc. | $6,567.10 | 01/16/2025 | Non-covered Recipient Entity CANCER AND BLOOD SPECIALTY CLINIC | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235929988 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,449.00 | 01/16/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175436361 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,147.00 | 01/16/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175436588 |
| Principal investigator 1 | Janssen Research & Development, LLC | $399.00 | 01/16/2025 | Non-covered Recipient Entity CANCER AND BLOOD RESEARCH CENTER LL C | A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivan | No dispute reported | 06/30/2026 | 1175436709 |